EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical Impact of Molecular Tumor Board Inclusion on Treatment Outcomes in Neuroendocrine Neoplasms

Maryam Barsch, Linda Gräßel, Patrick Metzger, Alexander von Werder, Johanna Ganz, Lioba Klaas, Lisanne Schulz, Annegrit Decker, Anna Dammer, Patrick Wenzel, Mathias Friedrich, Julia Falkenstein, Henriette Bertemes, Julia Kuehn, Cornelius Miething, Alisa Martina Lörsch, Johannes Jung, Anna Lena Illert, Atsuko Kasajima, Yasmin Dorusch, Elaine-Pashupati Dopfer, Anne Maria Schultheis, Silke Lassmann, Marianne Pavel, Martin Werner, Melanie Boerries, Justus Duyster, Roland M. Schmid, Carolin Mogler, Nicole Pfarr, Heiko Becker, Robert Thimme, Michael Quante, Sebastian Lange

Neuroendocrinology · 2026-05-20 · 1-15

DOI: 10.1159/000552650 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Neuroendocrine neoplasms (NENs) are rare and biologically heterogeneous tumors with limited evidence-based systemic treatment options, particularly in advanced disease stages. Molecular Tumor Boards (MTBs) offer an interdisciplinary framework for interpreting genomic alterations and identifying personalized treatment strategies. Methods: We conducted a retrospective two-center analysis of patients with NENs discussed at the MTBs of the University Medical Center Freiburg and the Technical University of Munich between 2019 and 2024. Clinical characteristics, molecular profiling results, MTB-based therapy recommendations, treatment implementation, and outcomes were evaluated. Overall survival (OS) was analyzed using a predefined 6-month landmark approach to account for immortal time bias. Treatment efficacy was further assessed using progression-free survival (PFS) and PFS2/PFS1 ratio. Results: A total of 87 patients were discussed at both MTBs, 74 of whom underwent molecular profiling. Actionable therapy recommendations were issued for 58 patients, and 20 patients ultimately received MTB-guided therapy. Molecular alterations frequently involved DNA damage repair pathways, immune-related biomarkers, and signaling cascades relevant to targeted therapy. 6-month landmark OS analysis demonstrated significantly improved OS for patients receiving MTB-guided therapy. At the individual level, 8 of 20 treated patients achieved a PFS2/PFS1 ratio >1.3. Conclusion: Molecular-guided precision oncology can provide clinically meaningful benefit for selected patients with NENs, despite limited overall implementation rates. Earlier integration of molecular profiling may increase the feasibility and impact of personalized treatment approaches in these rare tumor entities.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →